Vanguard Group
TLIS

Vanguard Group’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Vanguard Group’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,013
Closed -$269K – 4412
2024
Q2 		$269K Hold
31,013
– – ﹤0.01% 4121
2024
Q1 		$271K Hold
31,013
– – ﹤0.01% 4124
2023
Q4 		$231K Buy
31,013
+294
+1% +$1.92K ﹤0.01% 4199
2023
Q3 		$177K Sell
30,719
-370
-1% -$2.53K ﹤0.01% 4274
2023
Q2 		$224K Sell
31,089
-339
-1% -$2.46K ﹤0.01% 4296
2023
Q1 		$231K Sell
31,428
-1,516
-5% -$12.9K ﹤0.01% 4300
2022
Q4 		$220K Sell
32,944
-728
-2% -$6.38K ﹤0.01% 4294
2022
Q3 		$344K Sell
33,672
-3,220
-9% -$40.7K ﹤0.01% 4312
2022
Q2 		$450K Sell
36,892
-3,937
-10% -$62.3K ﹤0.01% 4316
2022
Q1 		$864K Sell
40,829
-7,513
-16% -$260K ﹤0.01% 4256
2021
Q4 		$2.91M Buy
48,342
+10,425
+27% +$780K ﹤0.01% 3886
2021
Q3 		$3.56M Buy
37,917
+1,590
+4% +$212K ﹤0.01% 3839
2021
Q2 		$6.01M Buy
36,327
+10,326
+40% +$1.75M ﹤0.01% 3496
2021
Q1 		$5.01M Buy
+26,001
New +$6.48M ﹤0.01% 3533

Other funds holding TLIS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Vanguard Group's TLIS Position: Q3 2024 in Review

Vanguard Group sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 31,013 shares — an estimated $269K sold.

Vanguard Group first reported a position in TLIS in Q1 2021 and held it in 14 quarters. The position peaked at $6.01M in Q2 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

  • Vanguard Group reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
  • Vanguard Group sold 31,013 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $269K.
  • Vanguard Group first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 14 quarters.
  • Vanguard Group's Talis Biomedical Corporation Common Stock position peaked at $6.01M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.